1Soltau J B, Zimmerman T J. Changing paradigms in the medical treatment of glaucoma[ J ]. Surv Ophthalmol,2002 ,47 ( Suppl 1 ) :2-5.
2Whitson J T. Glaucoma: a review of adjunctive therapy and new management strategies [ J ]. Expert Opin Pharmacother, 2007, 8 (18) :3237-3249.
3CAPRIOLI J, FASTERLAND D E, GROSS R L, et al. Preferred practice pattern for primary open-angle glaucoma[ C ]. San Francisco: American Academy of Ophthalmology, 2002 : 1-2.
4HUSAIN S, CROSSON C E. Role of PK cepsilon in PGF2alphastimulated MMP-2 secretion from human ciliary- muscle cells[ J]. J Ocul Pharmacol Ther, 2008,24(3) :268-277.
5ISHIDA N, ODANI-KAWABATA N, SHIMAZAKI A, et al. Prostanoids in the therapy of glaucoma[ J ]. Cardiovasc Drug Rev, 2006, 24(1) : 1-10.
6PERRY C M, MCGAVIN J K, CULY C R, et al. Latanoprost: an update of its use in glaucoma and ocular hypertension [ J]. Drugs Aging, 2003, 20(8):597-630.
7CHEN M J, CHEN Y C, CHOU C K, el al. Comparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angle-closure glaueoma[ J]. J Ocul Pharmacol Ther, 2007, 23 (6) :559-566.
8HOLMSTROM S, BUCHHOLZ P, WALT J, et al. Analytic review of bimatoprost, latanporost and travoprost in primary, open angle glaucoma[J]. Curr Med Res Opin, 2005, 21(11): 1875-1883.
9LIM K S, NAU C B, O'BYME M M, etal. Mechanism of action of bimatoprost, latanoprost, and travoprost in health subjects. A crossover study[ J ]. Ophthalmology, 2008, 115 (5) :790-795.
10CUNLIFFE I. New drugs in glaucoma therapy[ J ]. Hospital Medicine, 2003, 64(3) : 156-160.
